Evercore ISI Group Maintains Outperform on Health Catalyst, Raises Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
Evercore ISI Group has maintained an 'Outperform' rating on Health Catalyst and raised its price target from $8 to $10, indicating a positive outlook for the company's stock.
October 08, 2024 | 5:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Evercore ISI Group has maintained an 'Outperform' rating on Health Catalyst and increased the price target from $8 to $10, suggesting a positive short-term outlook for the stock.
The 'Outperform' rating and increased price target from a reputable analyst firm like Evercore ISI Group typically signals confidence in the company's future performance, likely leading to a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100